Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Des-1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Cincera Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cincera Therapeutics is developing an oral small-molecule inhibitor of Dihydroceramide desaturase 1 (Des-1), an enzyme that catalyzes the final step in the de novo synthesis of ceramides. By inhibiting Des-1, the drug aims to modulate the levels of bioactive lipids, specifically reducing ceramides and increasing dihydroceramides, to mitigate lipotoxicity, inflammation, and fibrosis. This therapeutic approach is being targeted at metabolic and fibrotic conditions, including non-alcoholic steatohepatitis (NASH) and fibrosis of the liver, kidney, lung, and heart. The program is currently in preclinical development, supported by funding from the Australian government's Biomedical Translation Bridge Program and Brandon Capital's Medical Research Commercialisation Fund.
- Other names
- Dihydroceramide desaturase 1 inhibitorCincera Des-1 inhibitor
02
Targets
DEGS1 (Delta(4)-desaturase, sphingolipid 1)
Beyond the preview
Go deeper on Des-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Des-1 inhibitor.